Investigation of FMS-Like Tyrosine Kinase 3 Mutation Frequency in Myelodysplastic Syndrome
International Blood Research & Reviews,
Page 23-31
DOI:
10.9734/ibrr/2021/v13i130163
Abstract
Introduction: FMS-Like Tyrosine Kinase Class 3 (FLT3) mutations harbor poor prognosis, high relapse, and decreased overall survival in acute myeloblastic leukemia (AML). This mutation is also known to be demonstrated in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia and acute lymphoblastic leukemia. This study included 94 MDS-diagnosed patients and we tried to investigate FLT3 mutation frequency (as tyrosine kinase domain-TKD and internal tandem duplication-ITD).
Materials and Methods: Polymerase chain reaction (PCR), restriction fragment length polymorphism, and agarose-gel electrophoresis methods were used to analyze the mutation. The blood samples were collected in K3-EDTA tubes, and total DNA was isolated using genomic DNA isolation kits (GeneMark, Cat No: DP023P). For the detection of FLT3-ITD mutation, PCR was performed to amplify a 330- base pair fragment of exons 11 and 12 of FLT3 using FAM (Carboxyfluorescein)-labeled ITD-11F and HEX (Hexachloro-Fluorescein )-labeled ITD-12R primers in a thermal cycler (Eppendorf). Similarly, to detect D835 mutation, a 115- bp region of exon 17 of the FLT3 gene region was amplified using primers.
Results: One patient was found FLT3-ITD positive (1.1%). The patient was 64-year-old and diagnosed with MDS-excess blast type 2 according to the World Health Organisation 2016 myeloid neoplasm classification. He transformed to AML within 19 months and subsequently died after 1 month. No patient with tyrosine kinase domain mutation was detected.
Conclusion: FLT3 mutation is considered a significant parameter to define prognosis in AML. The routine workup of FLT3 screening and the potential of targeting FLT3 inhibition for high-risk MDS may be taken into consideration in the future.
Keywords:
- Cytopenia
- FMS-like tyrosine kinase mutation
- myelodysplastic syndrome
- prognosis
How to Cite
References
DOI: 10.1159/000488712.
Daver N, Schlenk RF, Russell NH, Levis JM. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia 2019. 33:299–312.
Available: https://doi.org/10.1038/s41375-018-0357-9
Horiike S, Yokota S, Nakao M, Iwai T, Sasai Y, Kaneko H, et al. Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leuk: Off J Leuk Soc Am Leuk Res Fund UK. 1997; 11:1442–1446.
DOI: 10.1038/sj.leu.2400770.
Shih LY, Huang CF, Wang PN, Wu JH, Lin TL, Dunn P, et al. Acquisition of FLT3 or Nras mutations is frequently associated with progression of myelodysplastic syndrome to acute myeloid leukemia. Leukemia. 2004; 18: 466-75.
DOI: 10.1038/sj.leu.2403274.
Bacher U, Haferlach T, Kern W, Claudia H, Susanne S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92:744–752.
Available:https :// doi.org /10.3324 / haematol.10869
Daver N, Strati P, Jabbour E, Tapan K, Raja L, Sa W, et al. FLT3 mutations in myelodysplastic syndrome and chronic myelomonocytic leukemia. Am J Hematol. 2013; 88:56–59.
DOI: 10.1002/ajh.23345.
Xu F, Han R, Zhang J, Li Z, Wang J, Chu XL, et al. The Role of FLT3-ITD Mutation on de Novo MDS in Chinese Population. Clin Lymphoma Myeloma Leuk. 2019;19:e107-e115.
DOI: 10.1016/j.clml.2018.11.006.
Yu J, Li Y, Li T, Li Y, Xing H, Sun H, et al. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia. Exp Hematol Oncol. 2020;9:2.
DOI: 10.1186/s40164-019-0158-5.
Badar T, Szabo A, Sallman D, Komrojki R, Lancet J, Padron E, et al. Interrogation of molecular profiles can help in differentiating between MDS and AML with MDS-related changes. Leuk Lymphoma. 2020;61:1418-1427.
DOI:10.1080/10428194.2020.1719089.
Bezerra MF, Larrazábal BR, Lima AS, Mello MR, Pimentel RF, Weinhäuser I, et al. Screening for myeloid mutations in patients with myelodysplastic syndromes and AML with myelodysplasia-related changes. Hematol Transfus Cell Ther 2021;S2531-1379(20)31315-8.
DOI: 10.1016/j.htct.2020.10.967.
Arber DA, Orazi A, Hasserjian R, Jürgen T, Michael JB, Michelle M, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016. 127: 2391–2405.
DOI: 10.1182/blood-2016-03-643544.
Murphy MK , Levis M, Hafez MJ, Tanya G, Lisa CC, B Douglas S, et al. Detection of FLT3 Internal Tandem Duplication and D835 Mutations by a Multiplex Polymerase Chain Reaction and Capillary Electrophoresis Assay. J Mol Diagn. 2003:96-102.
DOI: 10.1016/S1525-1578(10)60458-8
Yamamoto Y , Kiyoi H, Nakano Y, Ritsuro S, Yoshihisa K, Shuichi M ,et al. Activating Mutation of D835 Within the Activation Loop of FLT3 in Human Hematologic Malignancies. Blood.2001; 97:2434-9.
DOI: 10.1182/blood.v97.8.2434.
Bibault JE, Figeac M, Hélevaut N, Céline R, Sabine Q, Shéhérazade S et al. Next-generation sequencing of FLT3 internal tandem duplications for minimal residual disease monitoring in acute myeloid leukemia. Oncotarget. 2015; 6:22812–22821.
DOI: 10.18632/oncotarget.4333.
Yalniz F, Dalle IA, Kantarjian H, Gautam B, Tapan K, Keyur P, et al. Prognostic Significance of Baseline FLT3-ITD Mutant Allele Level in Acute Myeloid Leukemia Treated with Intensive Chemotherapy With/Without Sorafenib. Am J Hematol.2019; 94:984-991.
Wei H, Wang Y, Zhou C, Dong L, Bingcheng L, Kaiqi L, et al. Distinct genetic alteration profiles of acute myeloid leukemia between Caucasian and Eastern Asian Population. J. Hematolo Oncol.2018; 11:18.
DOI: 10.1002/ajh.25553.
Larrosa-Garcia M, Baer MR. FLT3 inhibitors in acute myeloid leukemia: Current status and future directions. Mol Cancer Ther. 2017; 16: 991–1001.
DOI: 10.1158/1535-7163.MCT-16-0876.
-
Abstract View: 76 times
PDF Download: 43 times
